secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-10-17T23:59:59+00:00
Accession:  0001601485-24-000057
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics appoints CEO Robert Connelly as Principal Financial and Accounting Officer
--------------------------------------------------------------------------------

- Robert Connelly, already CEO and President, appointed as Principal Accounting Officer and Principal Financial Officer effective Oct 15, 2024.
- Connelly has nearly 40 years of life science leadership; previously CEO of Axcella Health, Pulmatrix, and Domantis (acquired by GSK).
- No family relationships with other directors or executive officers; no reportable transactions under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000057/0001601485-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000057/angn-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer